Ann Arbor-based University of Michigan Comprehensive Cancer Center joined forces with Tempus, a health technology company focused on personalized oncology care, to improve breast cancer treatment.
Tempus will use bioinformatics and machine learning to analyze molecular, phenotypic, therapeutic and outcomes data for hundreds of breast cancer patients. Tempus and U-M researchers will analyze this data alongside the university's patient-derived biological models, which alert providers to the drugs that will prove most effective for individual patients.
This agreement marks U-M's second collaboration with Tempus. The organizations partnered to bring U-M's DNA-sequencing panel, MI-ONCOSEQ, to cancer patients across the country in October.